Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02643355 · ClinicalTrials.gov registry record · NA
Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED
A NA study, sponsored by Hennepin Healthcare Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 70
- Enrollment target
NCT02643355 is a NA study that has completed, run by Hennepin Healthcare Research Institute. The registered enrollment target is 70 participants.
The verdict
NCT02643355, a NA study, has completed, sponsored by Hennepin Healthcare Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
Study Summary
Withdrawal from opioids is a clinical scenario that emergency department physicians encounter frequently. Patients who present with opioid withdrawal display symptoms such as agitation, anxiety, myalgias, abdominal pain, diarrhea, nausea, and vomiting. Currently, the standard treatment for opioid withdrawal is clonidine (an alpha-2 adrenergic agonist), as well as supportive cares (anti-emetics, intravenous fluids). Olanzapine is an atypical antipsychotic that is given frequently in the ED for many of the same symptoms that are seen in patients who are experiencing opioid withdrawal, however its use in this toxidrome has never been studied. The hypothesis of this study is that olanzapine is a safe and efficacious option when compared to clonidine for the treatment of opioid withdrawal in the emergency department.
Interventions
- DRUG Olanzapine
- DRUG Clonidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-06-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02643355
The ClinicalTrials.gov registry entry for NCT02643355 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hennepin Healthcare Research Institute, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olanzapine is the first listed.
NCT02643355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02643355 about?
NCT02643355 is a clinical study titled "Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED". Withdrawal from opioids is a clinical scenario that emergency department physicians encounter frequently. Patients who present with opioid withdrawal display symptoms such as agitation, anxiety, myalgias, abdominal pain, diarrhea, nausea, and vomiting. Currently, the standard treatment for opioid wi...
What is the current status of trial NCT02643355?
This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2015-11. Estimated completion is 2017-06-21.
What interventions are being tested in trial NCT02643355?
The interventions under investigation include: Olanzapine (DRUG), Clonidine (DRUG).
Who is sponsoring clinical trial NCT02643355?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.